Neuroprotection in Parkinson's disease: and now for something completely different?

Lancet Neurology

Volumn 5, Issue 12, 2006, Pages 990-991

  Lang, Anthony E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CEP 1347; GPI 1485; LEVODOPA; NEUROPROTECTIVE AGENT; PRAMIPEXOLE; PROPARGYLAMINE; RASAGILINE; RILUZOLE; ROPINIROLE; SELEGILINE; TCH 346; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; HUMAN; LETTER; NERVE CELL; NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 33750720918     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70605-6     Document Type: Letter

References (16)

1. Olanow C., Schapira A., LeWitt P., et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5 (2006) 1013-1020
2. Waldmeier P., Bozyczko-Coyne D., Williams M., and Vaught J. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72 (2006) 1197-1206
3. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321 (1989) 1364-1371
4. Shoulson I., and Parkinson Study Group PRECEPT Investigators. CEP-1347 treatment fails to favorably modify the progression of Parkinson's disease (PRECEPT) study. Neurology 67 (2006) 185
5. Rascol O., Olanow W., Brooks D., Koch G., Truffinet P., and Bejuit R. A 2-year, multicenter, placebo-controlled, double-blind, parallel-group study of the effect of riluzole on Parkinson's disease progression. Mov Disord 17 suppl 5 (2002) S39
6. Olanow C., Hauser R., Gauger L., et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38 (1995) 771-777
7. Palhagen S., Heinonen E., Haegglund J., et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 (2006) 1200-1206
8. Siderowf A., and Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 (2004) 561-566
9. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59 (2002) 1541-1550
10. Holloway R., Shoulson I., Kieburtz K., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284 (2000) 1931-1938
11. Whone A., Watts R., Stoessl A., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
12. Fahn S., Shoulson I., Kieburtz K., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508
13. Schapira A., and Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann Neurol 59 (2006) 559-562
14. Ravina B., Fagan S., Hart R., et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60 (2003) 1234-1240
15. Kieburtz K. Issues in neuroprotection clinical trials in Parkinson's disease. Neurology 66 10 suppl 4 (2006) S50-S57
16. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66 (2006) 664-671